Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line osimertinib plus anti-angiogenic VEGFR2-TKI in EGFR-mutant advanced non-small cell lung cancer
ChiCTR1800019835Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Objective response rate. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019835.